New Data Underscore the Utility of Rituximab in Treating Pemphigus Vulgaris

Genentech has announced that a phase 3 study of its brand-name rituximab, Rituxan, met its primary end point and demonstrated that treatment with rituximab is superior to treatment with mycophenolate mofetil in patients with moderate to severe pemphigus vulgaris (PV), a rate autoimmune disease that affects the skin and mucous membranes.  
Kelly Davio
October 15, 2019
Genentech has announced that a phase 3 study of its brand-name rituximab, Rituxan, met its primary end point and demonstrated that treatment with rituximab is superior to treatment with mycophenolate mofetil in patients with moderate to severe pemphigus vulgaris (PV), a rate autoimmune disease that affects the skin and mucous membranes.  

In the PEMPHIX study, a double-blind, double-dummy, active-comparator, parallel arm study in patients requiring oral corticosteroids, patients were randomized to receive either rituximab plus a placebo or mycophenolate mofetil plus a placebo for 52 weeks along with steroids, with the aim of tapering the steroid dose to 0 by week 24.

The primary end point at week 52 was the percentage of participants who achieved sustained complete remission without treatment failure; the study met this end point, with 40.3% of patients treated with rituximab, versus just 9.5% of patients treated with mycophenolate mofetil, achieving sustained complete remission without steroids for 16 weeks or more (P = .0001).

Secondary end points also favored rituximab, says Genentech: Patients treated with the biologic had lower cumulative oral corticosteroid doses, fewer flares, a greater likelihood of sustained complete remission, a lower likelihood of flares, and greater improvements in quality of life. Adverse events were consistent with the known profile of rituximab.

The results were presented in a late-breaking oral presentation during the 28th Congress of the European Academy of Dermatology and Venereology in Madrid, Spain.

The FDA first approved the brand-name rituximab for PV in 2018 on the basis of a different phase 3 study, the Ritux 3 trial, which showed that rituximab plus corticosteroids was superior to corticosteroids alone as first-line treatment for patients with PV. As a results of the findings, the International Bullous Disease Consensus Group reached an international consensus to recommend rituximab and corticosteroids as first-line therapy for moderate to severe PV.

The newly reported data could help Genentech and its innovator drug stay ahead of biosimilar competition, at least in the PV market; notably, the 2 currently FDA-approved biosimilar rituximab products, Pfizer’s Ruxience and Celltrion’s Truxima, are not approved to treat PV. The biosimilars both have so-called “skinny labels” due to patent protections and exclusivities for the reference drug. Neither drug has yet announced a launch date for the US marketplace.

x-button

Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2019 Intellisphere, LLC. All Rights Reserved.